Abstract 89P
Background
Current treatment strategies have improved gastric cancer (GC) patient survival yet disease progression risks remain considerable. Attention is directed to immune homeostasis mediators as indicators of therapy impact. Study aimed at investigating immunomodulatory cells & cytokines profiles in chemotherapy-naïve and Neoadjuvant chemotherapy (NACT) treated GC patients.
Methods
Prospective cohorts of 46 GC patients scheduled for surgical tumor excision first (CTn; n=18) or following NACT treatment (NACT; n=28) were included. NACT were grouped according to Mandard’s criteria into Responders (R;TRG1- 3;n=14) and Non-Responders(NR;TRG4-5;n=14). Peripheral blood samples for PBMCs and serum isolation were collected before surgery. Characterization of immune populations (cytotoxic CD3+CD8+ T-cells, CD4+FOXP3+ T-regs, CD3- CD16+CD56mid+ NKcells, CD3+CD16+ NKTcells & CD14+CD16-/CD14+CD16+/CD14-CD16+monocytes) & serum cytokines (IL-2, IL-4, IL-6, IL- 10, TNFa, IL-17a; by Cytometric Bead Arrays) was performed with FACS.
Results
NACT patient profiles revealed immune status differences between R and NR patients. R were defined by upregulated Tregs (p=0.016 vs NR), antitumor NKcells and intermediate (CD14+CD16+) monocytes (p=0.031 vs NR) and a concomitant profile of moderate increase of cytokines IL2, IL4, IL6 and IL10. In contrast, NR were characterized by increased classical (CD14+CD16-) monocytes, cytotoxic Tcells and NKTcells. NR also showed a reduction of IL2 and anti-inflammatory cytokines IL10 and IL4. CTn patients exhibited a similar to NR immunoprofile of increased cytotoxic populations, but also relatively increased Tregs, whilst cytokine patterns revealed predominance of pro- inflammatory TNFa and elevated IL4 and IL17a.
Conclusions
Responders were characterized by abundance of contributing to immunocompetence immune cells & antitumor acting cytokines whilst tumour progression in CTn & chemoresistant patients correlated with predominance of cytotoxic immunosurveilance populations & deprivation of immunoregulatory cytokines. Evidence highlights the immunomodulators profilling potential towards personalizing GC patient management.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
National and Kapodistrian University of Athens, Greece.
Funding
ERAPerMed 2019-275 (GRAMMY). ERAPerMed - Joint Transnational Call for Proposals (2019) for “Personalised Medicine: Multidisciplinary Research Towards Implementation”.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract